Frontier BioSciences

Frontier Biotechnologies is a commercial-stage biopharmaceutical company dedicated to discovering and developing innovative medicines for infectious diseases and other serious medical conditions. The company's flagship product, Aikening (albuvirtide), is the world's first long-acting HIV-1 fusion inhibitor and is currently approved and marketed in China. Frontier leverages its proprietary long-acting peptide technology to build a diverse pipeline targeting viral infections, chronic pain, and metabolic disorders. Headquartered in Nanjing, China, the company is publicly listed on the Shanghai Stock Exchange and maintains a global presence through research and development facilities in the United States.